A PHASE 1BOPEN-LABEL, MULTICENTER, DOSE ESCALATIONSTUDY TO ASSESSTHE SAFETY, TOLERABILITY AND PHARMACODYNAMIC EFFECTS OF A SINGLE DOSE OF PBFT02DELIVERED INTO THE CISTERNA MAGNA(ICM)OF ADULTSUBJECTS WITH FRONTOTEMPORAL DEMENTIA (FTD) AND MUTATIONS IN THE PROGRANULIN GENE (GRN)

Registry ID

PBFT02-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

PASSAGE BIO, INC.

Start date

2023-05-26

Last update

2021-04-16

Conditions

• FRONTOTEMPORAL DEMENTIA

Related clinical trials

• A PHASE 2 CLINICAL TRIAL OF INTRANASAL OXYTOCIN FOR FRONTOTEMPORAL DEMENTIA
• THE IMPACT OF EMOTIONAL MIMICRY AND OXYTOCIN ON FTD

View on source registry